Bortezomib 3.5mg Injection Bortrac 3.5

Trade Name: Bortrac

Manufacturer: Glenmark Pharmaceuticals Ltd

Presentation: Injection

Strength: 3.5mg

For what reason is Bortezomib 3.5mg Injection utilized in the treatment of different myeloma?

Bortezomib 3.5mg Injection is a proteasome inhibitor, which is a type of treatment for myeloma. Proteasomes are chemicals found in all cells that are fundamental for cell capacity and development. Bortezomib makes disease cells more delicate to its activities, driving them to kick the bucket or quit developing.

Is Bortezomib 3.5mg Injection curable?

Multiple myeloma treatment can typically help reduce symptoms and improve the overall quality of life. However, because myeloma is seldom curable, more treatment is required if the malignancy returns.

What are the Bortezomib 3.5mg Injection side effects?

  • The injection site may cause dizziness, lightheadedness, nausea, vomiting, lack of appetite, diarrhea, constipation, weariness, weakness, or pain/redness. Nausea, vomiting, and diarrhea are all common side effects.
  • Your primary care physician might prescribe drugs to forestall or reduce queasiness, retching, or loose bowels in certain conditions.

Read more

Is Bortrac causing you to lose your hair?

Hair thinning. Hair loss isn’t a direct side effect of Velcade, but it could be caused by other medications used alongside it. Individuals utilizing Velcade in addition to the cytotoxic drug cyclophosphamide, for instance, may encounter going bald.

How frequently is bortezomib administered?

VELCADE is administered intravenously twice weekly for two weeks, followed by a 10-day break. This interaction should be possible up to multiple times.

Bortezomib is a type of treatment?

Bortezomib is a proteasome inhibitor, which is a kind of disease treatment medication. Cells contain proteasomes. They aid the breakdown of proteins that the cell doesn’t need. Bortezomib restrains the proteasomes, making proteins collect inside the cell.

Is bortezomib a type of chemotherapy?

VELCADE (bortezomib) is a type of designated treatment chemotherapy. VELCADE has a place with the proteasome inhibitors class of medications. The FDA has given it the approval to treat multiple myeloma and mantle cell lymphoma.

What is the purpose of bortezomib?

Bortezomib is a medication that is utilized to treat different myeloma (a sort of disease of the bone marrow). Bortezomib is likewise used to treat mantle cell lymphoma patients (a quickly developing disease that starts in the cells of the safe framework). Bortezomib has a place with the antineoplastic specialist class of medications.

We are a Global Wholesaler and Exporter from India and work in more than 5 countries like UAE, Saudi, Oman, Qatar, and Myanmar. moving past you are looking for another product or brand click here.